Literature DB >> 1716486

Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application.

A Möller1, F Emling, D Blohm, E Schlick, K Schollmeier.   

Abstract

Three stable murine hybridoma cell lines, which secrete monoclonal antibodies (mAb) to human tumor necrosis factor alpha (TNF alpha), were established. None of the monoclonal antibodies cross-reacted with lymphotoxin, interleukin 2 (IL 2) or Interferon gamma (IFN gamma). The highly species-specific monoclonal antibody, designated as mAb 195, neutralizes the cytotoxic activity of human and chimpanzee TNF alpha. This antibody was further used during in vivo studies to neutralize human TNF alpha in a murine animal model. The mAb 114 is a weakly neutralizing antibody that binds to a different epitope of TNF alpha than mAb 195. mAb 114 shows a wide range of cross-reactivity with TNF alpha of the following species: dog, pig, cynomolgus, rhesus, baboon and chimpanzee. The mAb 199 binds to human TNF alpha, but does not neutralize the cytotoxic activity. The epitope recognized by this mAb is in close proximity to mAb 114. A reproducible, sensitive immunoassay for human TNF7 alpha has been developed using the antibodies mAb 199 and mAb 195. The test is performed within 6 hr and detects TNF7 alpha in serum samples, with a limit of detection of 5 to 10 pg/mL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1716486     DOI: 10.1016/1043-4666(90)90011-h

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells.

Authors:  Nalini K Vudattu; Ernst Holler; Patricia Ewing; Ute Schulz; Silvia Haffner; Verena Burger; Silvia Kirchner; Reinhard Andreesen; Günther Eissner
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

2.  Subchronic exposure of cardiomyocytes to low concentrations of tumor necrosis factor alpha attenuates the positive inotropic response not only to catecholamines but also to cardiac glycosides and high calcium concentrations.

Authors:  P Boekstegers; I Kainz; W Giehrl; W Peter; K Werdan
Journal:  Mol Cell Biochem       Date:  1996-03-23       Impact factor: 3.396

3.  Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia.

Authors:  P E Dekkers; T ten Hove; A A te Velde; S J van Deventer; T van Der Poll
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

4.  Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees.

Authors:  T van der Poll; M Levi; H ten Cate; J Jansen; B J Biemond; B L Haagmans; A Eerenberg; S J van Deventer; C E Hack; J W ten Cate
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

5.  Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Authors:  M Svenson; M B Hansen; K Bendtzen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood.

Authors:  M J Schultz; P Speelman; S Zaat; S J van Deventer; T van der Poll
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

7.  Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees.

Authors:  T van der Poll; J Jansen; M Levi; H ten Cate; J W ten Cate; S J van Deventer
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.